MAIA Biotechnology, Inc. — Director's Dealing 2023

Jan 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MAIA Biotechnology, Inc. (MAIA)
CIK: 0001878313
Period of Report: 2023-01-25

Reporting Person: Smith Stan (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-25	Common Stock	P	9	$4.25	Acquired	513337	Indirect
2023-01-26	Common Stock	P	227	$4.24	Acquired	513564	Indirect

Footnotes

F1: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.